Currently 940 clinical stage immuno-oncology agents being developed, report

11 December 2017

The USA-based Cancer Research Institute (CRI) last week published a report that provides a first-of-its-kind independent analysis of the global immuno-oncology (I-O) landscape, from agents in pre-clinical development to regulatory approval.

The report quantifies a significant number of I-O agents in development and this level of activity will likely result in an unparalleled number of advances in the field - but it also creates some challenges

The report, titled, “Comprehensive Analysis of the Immuno-Oncology Landscape,” published online in the Annals of Oncology, ESMO’s official journal, highlights findings from an analysis of CRI's robust, scientifically-curated database that actively tracks 2,004 I-O agents, of which 940 are already in clinical development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK